ArticleAnimal models and experimental medicine2026
Genome-wide network analysis identifies the lncRNA-92467/miR-205-5p/PTPRM/CAMs axis in a rat model of hypoxic pulmonary hypertension.
Article in Animal models and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHypoxic pulmonary hypertension (HPH) is a progressive chronic disorder characterized by elevated mean pulmonary arterial pressure. It severely impairs right ventricular function and ultimately causes right ventricular failure. Clarifying the complex pathogenesis of HPH remains a critical challenge.
methodsRat HPH models were established by exposure to a hypobaric hypoxia chamber for 4 consecutive weeks. Lung tissues were harvested for RNA sequencing. The Coding-Non-Coding Index (CNCI) and Coding Potential Calculator (CPC) were used to construct a competing endogenous RNA (ceRNA) network. Pulmonary artery endothelial cells were transfected with modified lncRNA-92467 or miR-205-5p to assess their regulatory functions. Finally, mice were injected with AAV-Control or AAV-PTPRM shRNA (2.5 × 10
resultsWe identified that lncRNA-92467 functions as a competing endogenous RNA (ceRNA) by competitively binding to miR-205-5p, thereby upregulating its target gene PTPRM. Knockdown of lncRNA-92467 significantly promoted pulmonary artery endothelial cell proliferation and migration. These effects were abolished by a miR-205-5p inhibitor, which also restored PTPRM expression. Functional assays confirmed that miR-205-5p enhanced cell proliferation and migration while inhibiting apoptosis; these effects were reversed by PTPRM overexpression. In vivo, exogenous PTPRM overexpression attenuated HPH progression in mice. Mechanistically, PTPRM directly targeted cell adhesion molecules (CAMs), which increased catenin production, thereby inhibiting abnormal cell proliferation and migration and promoting apoptosis.
conclusionsOur findings reveal a novel lncRNA-92467/miR-205-5p/PTPRM/CAMs regulatory axis in HPH pathogenesis. These results suggest that PTPRM may serve as a promising therapeutic target for HPH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.